The efficacy of high-intensity focused ultrasound (HIFU) used for the treatment of localized prostate cancers has been demonstrated over the past decade. We present our early results after HIFU used as a single session in patients with clinically localized prostate cancer. A total of 58 patients were treated using the Ablatherm HIFU device with or without transurethral resection of the prostate (TURP). HIFU failure was defined as the presence of a cancer remnant on repeated biopsies or three consecutive increases in the prostate-specific antigen (PSA) X1.0 ng/ml. The mean follow-up was 14 months (range, 6-21 months). After HIFU treatment, 78% of patients had a decreased PSA level to o0.5 ng/ml within 3 months. The median value of the last PSA was 0.6 ng/ml and the median nadir PSA was 0.2 ng/ml. The success rates of HIFU were 85, 77 and 47% in low-, intermediate-and high-risk groups, respectively. The HIFU failure rate was closely associated with clinical stage, presence of cancer on TURP chips and nadir PSA on univariate analysis. However, the only significant predictor for HIFU failure was the nadir PSA value by multivariate Cox regression analysis. The operation-related complications were minimal. Although both the period and number of patients were limited to evaluate the clinical efficacy, HIFU appears to be a safe and effective treatment option in selected patients with prostate cancer.
Introduction
Even though radical prostatectomy has been considered the standard treatment in patients with organ-confined prostate cancer, 1, 2 it is still associated with considerable operation-related morbidities. 3 The application of minimal invasive therapy, since the 1990s, has become a more common option for patients with localized prostate cancer, who are not suitable for more extensive surgery. 4 High-intensity focused ultrasound (HIFU) is capable of causing coagulation necrosis in targeted tissue by the conversion of mechanical energy into heat and a cavitation effect. 5 Previous reports have described HIFU treatment is a valuable alternative for well-and moderately differentiated localized prostate cancers as well as for local recurrence after external beam radiation therapy. 6, 7 We report our preliminary experience in 58 patients treated with HIFU for clinically localized prostate cancer. In addition to the clinical results, we evaluated the prognostic factors for outcomes after treatment with HIFU.
Materials and methods
We performed transrectal HIFU therapy using an Ablatherm HIFU device (EDAP SA, Lyon, France). There is an endorectal firing head that incorporates both a 7.5 MHz ultrasound imaging probe and a 3 MHz piezoelectric treatment transducer. The shots are delivered 1.7 mm apart with 5 s duration and a 5-s delay between each shot. The targeted lesion is cigar-like in shape and measures between 19 and 24 mm in length and 1.7 mm in diameter.
All of the procedures were conducted under spinal anesthesia. A suprapubic catheter was placed preoperatively to guarantee adequate urinary drainage. Combined transurethral resection of the prostate (TURP) was performed to reduce prolonged urinary retention before an initiation of HIFU therapy. Immediately after the TURP, the patient was placed in the right lateral decubitus position. Following localization of the targeted volume boundaries, using the integrated ultrasound imaging system, contiguous HIFU shots were delivered. The computer-driven HIFU treatment was delivered slice-by-slice from the apex to the bladder neck to treat the whole prostate. The suprapubic catheter was removed after the test if the postvoid residual urine was less than 50 ml.
From February 2004 to April 2005, HIFU therapy was performed in 62 patients, all of whom were diagnosed with clinically localized prostate cancer. The selected population included patients with clinical stage T 1À2 , prostate-specific antigen (PSA) value o30 ng/ml and no evidence of metastasis on preoperative endorectal coil magnetic resonance imaging (MRI) and bone scan. All patients were unsuitable for radical prostatectomy because of their age or co-morbidities, or were not willing to undergo surgery. Out of 62 patients, 58 patients who were available for follow-up for 6 months or longer were included in this study. The disease-related risk was divided into three subgroups according to the pretreatment clinical stage, PSA and Gleason score. 8 Patients generally were scheduled to assess the serum PSA 1 month postoperatively, then every 3 months in the first year and every 6 months thereafter. In the case with a rising PSA equal to or exceeding 1.0 ng/ml, PSA was more frequently monitored than the scheduled interval. Repeated biopsies of the prostate were performed in cases with consecutive or significant increase(s) of the PSA level. Failure of HIFU was defined as any cancer remnant on follow-up repeat biopsy or three consecutive increases in the PSA X1.0 ng/ml. The date of HIFU failure was considered according to the criteria by the American Society for Therapeutic Radiology and Oncology (ASTRO). 9 A persistent PSA level was scored as an HIFU failure at time zero. In patients with HIFU failure, endorectal MRI and/or bone scan were performed to determine the evidence of local recurrence or distant metastasis.
All continuous variables were expressed as means7 s.d. The distribution of HIFU failure-free survival time was calculated according to the Kaplan-Meier curves. The HIFU failure-free survival rates according to the variables studied were compared by log-rank tests. A multivariate Cox proportional hazards model was used to determine the predictors of HIFU failure. A P-value o0.05 was adopted as the level of statistical significance.
Results
The mean follow-up was 1474 months (range, 6-21 months). The baseline characteristics of the 58 patients undergoing HIFU therapy are listed in Table 1 . Of them, 17 patients (29%) received neoadjuvant hormonal therapy before the visit to our hospital. All hormonal therapy was discontinued at the time of the HIFU procedure.
The mean treated volume of the prostate was 31.577.9 cm 3 with a mean of 4827114 HIFU shots per session. A majority of patients (91%, 53/58) received combined TURP. The mean resection weight of the prostate was 10.379.7 g (range, 1-41 g). The histological examination of TURP chips revealed cancer in 64% (34/53).
At a mean 14-month follow-up, 40 patients (69%) showed a successful outcome following a single session of HIFU. None of these patients required adjuvant therapy. When stratified according to risk, HIFU success was observed in 85% (11/13), 77% (20/26) and 47% (9/19) in low-, intermediate-and high-risk groups. After HIFU treatment, 78% (45/58) of the total number of patients had a decreased PSA level to o0.5 ng/ml within 3 months. The median value of the last PSA was 0.6 ng/ml (range, 0.01-15.4 ng/ml). The median nadir PSA value was 0.2 ng/ml (range, 0.01-7.60.2 ng/ml) and the mean time to reach the nadir level was 8.874.1 weeks. The initial mean PSA level in patients with HIFU failure was much higher than in those with HIFU success (13.0 vs 9.9 ng/ml), but this finding did not show statistical significance (P ¼ 0.064; Mann-Whitney test).
The Kaplan-Meier estimated curves based on several clinical variables to predict HIFU failure-free survival rates are shown in Figure 1 . The clinical stage, identification of cancer on TURP prostate chips and nadir PSA level influenced significantly HIFU outcome (Figure 1a-c) . The 18-month actuarial HIFU failure-free rate for those with T 1 and T 2 was 81 and 51% (P ¼ 0.041; log-rank test). In cases where cancer was present on TURP chips, the 18-month HIFU failure-free rate was lower than those with absence of cancer on specimens (54 vs 90%, P ¼ 0.022). The 18-month HIFU failure-free rate was the highest for patients with a PSA nadir level less than 0.5 ng/ml compared to that equal to or greater than 0.5 ng/ml (85 vs 0%, Po0.001). However, there was no statistically significant difference in disease-free rates according to PSA, Gleason score and prostate volume. According to the risk stratification previously defined, 8 the prognosis for the low-and intermediate-risk group was more favorable than that of the high-risk group although it did not reach statistical significance (Figure 1d ). In multivariate analysis using the Cox proportional hazards model, the nadir PSA value was a statistically independent predictor for HIFU outcome, whereas other variables were not ( Table 2) .
The suprapubic tube could be removed at a mean of 15 days (range, 3-43 days) after the procedure. The mean hospital stay was 3.5 days. The HIFU-related complications were well tolerated. Mild stress urinary incontinence (grade 1) was reported by 16% of the patients, HIFU therapy for prostate cancer HM Lee et al which resolved spontaneously or after management with pelvic floor muscle exercise. Delayed passage of necrotic debris was observed in eight patients (14%). They were treated with cystoscopic removal of the debris. Urethral stricture, after HIFU therapy, was identified in four patients who were managed with urethral bougienation. Two patients experienced acute urinary retention after removal of the suprapubic catheter. Of these two patients, one patient was treated with temporary placement of a urethral catheter for 5 days and the other underwent a second TURP owing to remnant floppy tissues at the previous TURP site.
Of the total patients in this study, 18 had an HIFU failure. Ten of these patients exhibited residual cancers on repeated biopsies during a median follow-up of 10 months (ranging from 3 to 14 months). They underwent HIFU re-treatment (n ¼ 4) or external beam radiation therapy (n ¼ 4). Out of four patients who underwent a second HIFU, one patient has received intermittent androgen deprivation owing to identification of bone metastasis after 5 months of HIFU re-treatment. Two patients are scheduled to receive either HIFU or radiation therapy. The remaining eight patients, without remnant positive biopsies, are being followed by watchful waiting HIFU therapy for prostate cancer HM Lee et al because of steady increase or relatively stable PSA level (mean last PSA value 1.3 ng/ml, ranging from 1.1 to 1.6 ng/ml).
Discussion
The first clinical application using the Ablatherm HIFU device as a single treatment module for the treatment of locally confined prostate cancer was carried out by Gelet et al. 10 in 1996. These investigators reported that a satisfactory local control with negative control biopsies was achieved in 50% of patients. At that time, the prototype device had a 2.25 MHz therapy transducer. Thereafter, modifications of the treatment device and software have been made. As a consequence, the frequency has been increased to 3 MHz, whereas the interval between the treatment shots has been shortened. This preliminary result of HIFU has been confirmed thereafter. [11] [12] [13] As these early results demonstrated that transrectal HIFU can obtain a local control of prostate cancer, the uses of HIFU have been widely applied in Europe. The European multicentric study reported the results at 1-year follow-up for 402 patients with localized prostate cancer (T 1À2 N 0Àx M 0 ).
14 After HIFU treatment, 87.2% of the 288 patients, who had prostatic biopsy results that could be assessed, had negative finding. When stratified according to risk group, negative biopsy rates were observed in 92.1, 86.4 and 82.1% in the patients with low, intermediate and high risk. Blana et al. 15 described a 5-year experience from a study of 146 patients with biopsy-proven T 1À2 N 0 M 0 prostate cancer. Included patients had a PSA level p15 ng/ml and a Gleason score p7. They reported that 87% of the patients had a PSA value o1 ng/ml and 93% had negative follow-up biopsies with a mean 22.5 months of follow-up. With the aim to reduce prolonged urinary retention after HIFU treatment in the immediate follow-up period, treatment combining TURP and HIFU was studied. 16, 17 Those authors emphasized that the patients who underwent HIFU as a primary therapy combined with TURP generally have low treatment-related morbidities without affecting oncologic outcomes. Recently, Uchida et al. 18 described the encouraging results of other HIFU machine using a Sonablate device (Focus Surgery Inc., Indianapolis, IN, USA) with a mean 23.3 months of follow-up. They reported that the PSA nadir is a useful predictor of biochemical recurrence.
On univariate analysis, the clinical stage T 2 , presence of cancer tissue on TURP chips and a nadir PSA X0.5 ng/ml were related to poor HIFU success rates. Prostate cancers are most commonly detected in the peripheral zone (75-85%) although they may arise from any anatomical zone. Most transition zone cancers detected by transrectal ultrasound-guided needle biopsy will be those associated with tumor foci at the peripheral zone. 19 Only 2-7% of prostate cancers are confined exclusively to the transition zone. 19, 20 None of the patients showed isolated transition zone tumors by needle biopsy specimens in our study. Therefore, the patients with cancer tissue on TURP chips in this study had multizonal tumors involving both peripheral and transition zones. Patients with low nadir PSA after radiation therapy have been considered to have a favorable prognosis. 21, 22 Our study supports these findings, especially in patients with a nadir PSA level o0.5 ng/ml.
A limitation of our study was the small number of patients, which restricted statistical evaluation. However, the nadir PSA value was the most powerful indicator for predicting HIFU failure. Therefore, patients should be monitored carefully when the nadir PSA has not dropped below 0.5 ng/ml. These patients are ultimately expected to become HIFU failures sooner or later, and may be candidates for salvage therapy. Treatment failure appeared to be more common in patients with a highrisk classification before treatment. Out of our cancer cohort, 19 patients (33%) had more than one high-risk variable such as T 2c or PSA 420 ng/ml or a Gleason score of 8. Consequently, overall treatment success rate was somewhat lower than previous reports because of this unique characteristic of our patients. The 18-month HIFU failure-free rate was 80 and 40% in patients with low or intermediate and high risk (P ¼ 0.028; log-rank test). Hence, it would be expected that a satisfactory local control could be achieved in low-or intermediate-risk patients. In order to achieve good outcomes with this minimally invasive therapy, the application of more narrow criteria may be necessary. At the time of this study, we did not include the outcomes of patients with HIFU re-treatment because of the short term of follow-up after the second HIFU therapy. Therefore, this preliminary result represents pure changes of PSA after a single session of HIFU. Another limitation was the absence of routine control biopsies following HIFU treatment; a negative biopsy rate could not be calculated in our study. However, all patients with repeated biopsy-proven cancers fulfilled HIFU failure criteria.
Although the follow-up period and number of patients in our study were not sufficient to assess clinical efficacy, HIFU treatment for localized prostate cancer can be considered as an alternative therapeutic modality for patients who are not candidates for radical prostatectomy, especially in the cases with low or moderate risk. The nadir PSA value was found to be an important prognostic factor in our study.
